The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:

  • Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma
  • Gene signature combinations improve prognostic stratification of multiple myeloma patients
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
  • Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case.




This manuscript intends to explain prophylaxis strategies for venous thromboembolism (VTE).





This statement made by the IMWG responds to the Mayo Clinic’s statement on using bisphosphonates (BPs) on patients with multiple myeloma.





This revised form of International Response Criteria may possibly be widely used in future clinical trials.





This research focuses on unifying a multiple myeloma staging system around the world called the International Staging System (ISS).





These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.